BenevolentAI
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
46 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Investor Presentation
October 2022
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Investor Day
September 2022
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Related slides by other companies
Ocuphire Pharma
Results
October 2022
oral treatments in clinical development | Ocuphire Pharma
ATAI
Investor Presentation
October 2023
demonstrated safety level and plasma concentrations of in line with previous trials phase study trial design results summary | ATAI
ATAI
Investor Presentation
January 2024
demonstrated safety level and plasma concentrations of in line with previous trials potential therapeutic plasma levels no serious adverse events reported asymptomatic prolongation phase study trial design results summary | ATAI
ATAI
Investor Presentation
January 2024
results from completed phase sad study showed had a favorable safety profile and was well tolerated whilst demonstrating dose proportionate profile | ATAI
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io